Subtle, cumulative, slow-onset. Like the V4/V5 antioxidant quartet (astaxanthin, curcumin, NAC, apigenin), this is not a felt supplement.

• Onset: No acute felt effect. Plasma OPC monomers peak at 1-3 hours; tissue accumulation takes 2-4 weeks; clinical endpoints typically need 6-12 weeks. Allergic rhinitis specifically requires 4-8 weeks of pre-loading before allergen exposure.
• Peak/plateau: After 4-8 weeks of consistent dosing, observable changes might be: less leg heaviness / cramping after long days standing, smoother skin, fewer seasonal allergy episodes (if pre-loaded), and — for older / vascular-compromised users — measurable BP, FMD, ED improvements. For Dylan (20yo healthy), the felt benefits will be subtle to imperceptible.
• Taper: Effects fade over 2-4 weeks after stopping. No withdrawal — gradual loss of the cumulative protection.
• What it does NOT feel like: Not a stimulant, not a focus enhancer, not a mood lifter, not an analgesic. The mechanism is "vascular + collagen + antioxidant insurance." Expect minimal acute change.

For Dylan specifically: most likely felt benefits would cluster around (1) gym pump / vascular reactivity (subtle, hard to attribute), (2) seasonal allergy reduction if applicable (more noticeable if pre-loaded before pollen season), and (3) very slow background "less inflammation" sense layered on top of the existing V4/V5 antioxidant baseline. Don't expect Tuesday-afternoon-different.

• Tolerance buildup: None reported across multi-month studies. Mechanism is enzymatic (eNOS) + structural (collagen binding) + chemical (radical scavenging), not receptor-mediated.
• Recommended cycle: None. Daily continuous use is the standard protocol in all clinical trials (4 weeks to multi-year).
• Reset protocol: Not applicable.
• Long-term safety: Multi-year EU market use with no population-level safety signal. Decades of human exposure since the 1980s.

Synergistic with

• L-arginine + L-citrulline: Strongly synergistic for endothelial NO. L-arginine + L-citrulline provide NO substrate; Pycnogenol upregulates eNOS expression + activity. Stanislavov 2003 ED RCT is the canonical example (80%+ ED improvement vs each alone). Same mechanism likely applies to general vascular reactivity, gym pump, BP — though specific RCTs outside ED are thinner. This is the highest-leverage Pycnogenol pairing. Not in Dylan's V4/V5; would be a new add-on.
• vitamin C (Dylan's V4 CGN 500 mg): Vitamin C regenerates oxidized OPC monomers (similar to vitamin C → vitamin E recycling); aqueous-phase + polyphenol-phase coverage. Layered antioxidant network. Already in V4 — no change needed.
• vitamin E (alpha-tocopherol): Layered membrane + plasma + vascular antioxidant defense. No formal RCT pairing for pine bark + vitamin E specifically but mechanism is solid.
• omega-3 / DHA (Dylan's V4 Carlson DHA Gems): Both anti-inflammatory at different mediator levels (DHA → resolvins; pine bark → NF-κB / 5-LOX). No interaction. Take at same breakfast meal.
• astaxanthin (Dylan's V5 add): Different antioxidant compartments (astaxanthin = lipid membrane bilayer; pine bark = plasma + vascular wall + collagen). Layered, not redundant. Take together.
• curcumin (Dylan's V4 Doctor's Best Curcumin Phytosome): Both anti-inflammatory via overlapping NF-κB / COX-2 pathway. Mild redundancy — curcumin is the better-studied anti-inflammatory at the inflammatory cytokine endpoint; pine bark adds the vascular / endothelial / collagen angle that curcumin doesn't cover as cleanly. Layered, not redundant. Take together.
• n-acetyl-cysteine (NAC) (Dylan's V4 Swanson NAC): Different mechanism (GSH precursor); layered antioxidant network. No interaction.
• apigenin (Dylan's V5 add): Both flavonoid-class polyphenols; different targets (apigenin = CD38/NAD+ + senomorphic; pine bark = OPC + endothelial). Layered. No interaction.
• resveratrol / quercetin / grape seed extract: All polyphenols, layered antioxidant defense. Grape seed extract has the most overlap (also primarily OPCs) — choose one, not both, for cost efficiency.
• CoQ10 / ubiquinol: Mitochondrial-membrane antioxidant; complementary. Useful endothelial-function pairing in older / hypertensive populations.
• alpha-lipoic acid: Universal antioxidant (water + lipid soluble); complementary; particularly relevant in diabetic / metabolic populations.
• boswellia (5-LOX inhibitor): Both 5-LOX-targeting; potentially synergistic for allergic rhinitis or asthma adjunct. Not formally tested.

Avoid stacking with

• High-dose anticoagulants (warfarin, DOACs) + high-dose Pycnogenol (>200 mg/day): Additive bleeding risk. Watch INR if on warfarin. Not relevant to Dylan.
• High-dose aspirin / NSAIDs at chronic dosing + Pycnogenol: Modest additive antiplatelet effect. Not clinically alarming for occasional NSAID use; flag for athletes on chronic NSAID regimens or pre-surgical patients.
• Active autoimmune flare without prescriber clearance. Pycnogenol's immune modulation is mostly anti-inflammatory, but unpredictable in active autoimmune disease.
• Grape seed extract at full dose for both — redundant OPC class. Pick one.

Neutral / safe co-administration

• All V4 stack items: NAC (no interaction), citicoline, magnesium (glycinate + threonate), fish oil (no interaction), phosphatidylserine, rhodiola, theanine, glycine/tryptophan, D3 + K2, beta-alanine, vitamin C (mild synergy), creatine.
• All V5 planned items: modafinil, bromantane, Adamax/Semax, ALCAR, apigenin (no interaction), taurine, astaxanthin (layered), L-tryptophan.
• Caffeine — no interaction, safe.

Pine bark / Pycnogenol has a relatively clean interaction profile compared to curcumin or grapefruit juice. Worth flagging:

• Anticoagulants (warfarin, DOACs, heparin): Mild antiplatelet activity at high doses (>200 mg/day) + theoretical CYP2C9 effect. Case reports of INR elevation with warfarin. Watch INR on warfarin patients adding Pycnogenol; clinically negligible at <100 mg/day.
• Antiplatelets (aspirin, clopidogrel, ticagrelor): Additive antiplatelet effect; theoretical increased bleeding risk. Magnitude small at supplement doses.
• Antihypertensives (ACEi, ARB, CCB, beta-blockers, thiazides): Mild additive BP-lowering effect. Worth flagging for hypertensive patients on multi-drug regimens. Not relevant to Dylan.
• Antidiabetics (metformin, SGLT2i, GLP-1, insulin, sulfonylureas): Mild additive glucose-lowering effect. Could push hypoglycemia risk in tightly-controlled T2D patients on insulin or sulfonylureas. Not relevant to Dylan.
• Immunosuppressants (cyclosporine, tacrolimus, methotrexate): Theoretical interaction via mild immune modulation + minor CYP effects. Avoid in transplant patients without prescriber clearance.
• CYP3A4 substrates: Minor in-vitro CYP3A4 inhibition reported; clinical relevance at supplement doses appears negligible. Not the same magnitude of concern as grapefruit juice or curcumin.
• Hormonal contraception: No documented interaction; theoretical SERM-like activity is sub-clinical at supplement doses.

For Dylan: not on any of the watch-list drugs. No drug interactions of concern in V4/V5 stack.

Limited published pharmacogenomic data on Pycnogenol specifically:

• eNOS polymorphisms (NOS3 G894T, T-786C): Carriers of low-NOS-activity variants might theoretically benefit more from Pycnogenol's eNOS upregulation. No human RCT has stratified by NOS3 genotype. APOE4 carriers and metabolic-syndrome patients might also benefit more given baseline endothelial dysfunction.
• CYP2C9 / CYP3A4 variants: Minor polyphenol metabolism via these enzymes; clinical impact small at supplement doses.
• GSTM1 / GSTT1 null genotypes: Reduced glutathione transferase → theoretically reduced clearance of polyphenol metabolites; magnitude small. Not clinically actionable.
• APOE4 carriers: Theoretical interest because endothelial-protective antioxidants might be more useful in APOE4-driven cerebrovascular dysfunction. No human RCT stratified.
• MTHFR variants: Pycnogenol's homocysteine-lowering effect (modest, in T2D RCTs) might be larger in MTHFR C677T homozygotes with elevated homocysteine. Speculative.

When 23andMe results land (~June 2026), no pre-emptive Pycnogenol dose adjustment expected. If APOE4 returns positive, the cognitive / cerebrovascular rationale strengthens slightly (still secondary to V4/V5 antioxidant quartet).

Dylan's recommendation IF added: Healthy Origins Pycnogenol 100 mg from iHerb at 100-200 mg/day — Horphag-branded for batch quality, fits existing iHerb V4 channel, ~$25-35/mo at 100 mg or ~$50-70/mo at 200 mg. If budget-sensitive or not committed: NOW Foods Grape Seed Extract is the credible cheap alternative for the OPC mechanism without the Pycnogenol-specific clinical evidence.

• Baseline (before starting / on June 2026 panel if added):

  • Lipid panel (TC, LDL-C, HDL-C, TG) — expect mild improvements in dyslipidemia, neutral in healthy young adults.
  • hsCRP — primary inflammation marker; expect ↓ after 8-12 weeks at adequate dose.
  • Fasting glucose, HbA1c, fasting insulin — expect mild improvements; verify no worsening.
  • Blood pressure (resting, ideally home cuff over multiple readings) — expect ~3-4 mmHg systolic ↓ in hypertensive populations; minimal in normotensive young adults.
  • Liver panel (ALT, AST, ALP, GGT) — baseline; no DILI signal documented but standard supplement vigilance.
  • CBC + iron panel — baseline; OPCs have mild iron-chelation potential at very high doses; magnitude smaller than curcumin.
  • MDA, oxidized LDL, isoprostanes — optional oxidative stress markers; specialty panel; expect ↓.
  • Microalbumin (urine) — relevant if metabolic syndrome / T2D / hypertension; expect ↓.
  • Subjective: leg heaviness / cramping rating, allergic rhinitis severity (if pre-loading), gym pump / vascular reactivity (subjective), sleep, mood.

• During use (every 6 months):

  • Lipid panel (looking for HDL stable / ↑, LDL stable / ↓, TG stable / ↓).
  • hsCRP (looking for ↓).
  • Fasting glucose, HbA1c (looking for stable / ↓).
  • BP (looking for stable / ↓ if hypertensive).
  • Liver panel (looking for stable).
  • Subjective endpoints (leg heaviness, allergic rhinitis, ED if relevant).

• Post-cycle: N/A — no cycling.

For Dylan specifically: piggyback on the June 2026 baseline panel. No additional bloodwork solely for Pycnogenol needed at this stage. If added, reassess at 8-12 weeks against subjective endpoints; drop if no observable benefit.